The Numbers, Straight Up

On June 1, 2026, the Coalition for Epidemic Preparedness Innovations — known as CEPI — announced it is committing up to $62 million across three organizations to fast-track vaccines against Ebola Bundibugyo, the specific strain currently spreading through eastern Democratic Republic of Congo and Uganda.

Moderna gets the lion's share: up to $50 million to fund preclinical work and Phase 1 clinical studies of its mRNA-based Bundibugyo vaccine candidate, according to Reuters and BioSpace. The University of Oxford, with manufacturing by the Serum Institute of India, gets up to $8.6 million. The International AIDS Vaccine Initiative gets an initial $3.2 million.

There are currently zero approved vaccines or treatments for Ebola Bundibugyo. These are early-stage programs.

Where the Outbreak Stands Right Now

The current numbers, per the Africa CDC and the World Health Organization: 282 confirmed cases, 42 deaths, and roughly 1,100 suspected cases inside the DRC. Beyond Congo's borders, nine confirmed cases in Uganda, including one death.

Global health agencies have formally declared this a public health emergency.

The situation on the ground extends beyond medicine. According to ZeroHedge and Reuters, locals in Ituri Province recently set fire to an Ebola treatment center run by the Alliance for International Medical Action after being stopped from retrieving the body of a suspected victim for a traditional funeral. Deputy Senior Commissioner Jean-Claude Mukendi confirmed the incident, saying the crowd did not understand burial protocols. Two tents — eight beds total — were destroyed.

When CEPI chief Richard Hatchett spoke to Reuters, he acknowledged the "challenging security situation" in eastern Congo will make trials complex. Vaccine development is already unpredictable. Running trials in an active conflict zone where locals are burning treatment centers compounds the difficulty significantly.

What Moderna Is Bringing to This

Moderna's Bundibugyo candidate uses the same mRNA platform that produced Spikevax, the company's COVID-19 vaccine, according to BioSpace. The existing CEPI-Moderna partnership — formed in late 2023 — was already focused on using mRNA technology for epidemic and pandemic threats. This commitment extends that relationship into an active emergency.

CEPI's $50 million will fund not just Phase 1 trials but manufacturing scale-up so that if early data looks promising, large Phase 2/3 trials can launch immediately without waiting for production ramp-up. That approach reflects lessons from COVID — have the manufacturing ready before you need it.

Moderna has prior experience with Ebola mRNA work. Back in January 2023, the U.S. government signed a $25 million contract with scientists at the University of Texas Medical Branch at Galveston partnered with Moderna — $13.5 million over three years to design, manufacture and test mRNA Ebola vaccines, with up to an additional $11.1 million for alternative delivery methods, according to UTMB. That earlier contract was focused on protecting U.S. military personnel. The current CEPI investment is a separate, newer, and larger commitment aimed at the active outbreak.

The Oxford and IAVI Candidates

Oxford's shot — ChAdOx1 Bundibugyo — uses the same viral vector platform that underpinned the Oxford/AstraZeneca COVID-19 vaccine, according to CNBC Africa. Oxford and the Serum Institute demonstrated last year, during a Rift Valley Fever outbreak in Mauritania and Senegal, that they could manufacture and deploy trial-ready doses rapidly in an active outbreak. That track record is why they're in the mix.

IAVI's candidate uses the same technology as Merck's Ervebo, the approved vaccine for Ebola Zaire — the original strain. It has shown survival benefit in animal studies. An approved vaccine for one strain does not necessarily work on Bundibugyo. These are different viruses.

What Mainstream Coverage Is Missing

Most mainstream outlets frame this as a straightforward "Moderna gets money to fight Ebola" story.

Moderna cut investment in late-stage infectious disease vaccine studies earlier this year after the Trump administration's health agencies shifted positions on vaccines, according to BioSpace. The company is simultaneously dealing with political pressure from Washington and trying to rebuild its image after rough post-COVID financial performance.

This CEPI deal represents externally funded work for Moderna. CEPI — not U.S. taxpayers — is footing this bill. That's a meaningful distinction.

Hatchett also told Reuters vaccine development is unpredictable and the security situation is genuinely dangerous. The mainstream framing implies shots in arms are coming soon. Hatchett said vaccines are on "a not infinitely distant horizon" — a careful way of saying early deployment is uncertain.

What This Means for Regular People

If you're in the DRC or Uganda, no vaccine is coming in time for this outbreak. The $62 million is about building a tool for the next Bundibugyo outbreak — or preventing this one from spreading further.

If you're a U.S. taxpayer, you're not funding this directly. CEPI is doing it. That's the proper role for a global health coalition — absorbing early-stage risk on diseases that don't yet have a commercial market.

If you're watching Moderna's stock, BioSpace notes the company's shares have already gotten a bounce from infectious disease fears tied to recent hantavirus developments. This announcement adds momentum to that narrative.

$62 million for a vaccine race against a virus killing people in a war zone, with no approved treatment in existence and trials that haven't even started. The science is real. The urgency is real. The timeline remains uncertain.